Which One is More Effective Filgrastim or Lenograstim for Febrile Neutropenia with Solid Tumors

The chemotherapy-induced neutropenia causes mortality and morbidity at a significant rate (Aapro et al., 2011; Fontanella et al., 2014). Fever is frequently observed during chemotherapy-induced neutropenia. Neutropenia-related fever could be encountered for at least once in 10-50% of patients with solid tumor and >80% of patients with hematological malignancy (Freifeld et al., 2011). In patients with febrile neutropenia (FN), it is generally required to decrease the dose of chemotherapy drugs or delay the treatment, which causes the failure of implementing an efficient treatment (Aapro et al., 2011; Freifeld et al., 2011). In the primary prophylaxis, granulocyte-colony stimulating factors (G-CSFs) are started with the first dose of chemotherapy before the presence of neutropenia and fever. Primary prophylaxis decreases the risk of chemotherapy-induced febrile neutropenia in patients with solid tumor or lymphoma (Cooper et al., 2011). However, since this approach brings along a high additional cost,